EGLN3

EGLN3 (Egl-9 Family Hypoxia-Inducible Factor 3), also known as PHD3 (Prolyl Hydroxylase Domain-containing Protein 3), is an enzyme that in humans is encoded by the EGLN3 gene. This protein is a member of the EGLN family, which plays a significant role in the cellular response to oxygen levels. Specifically, EGLN3 is involved in the hydroxylation of the hypoxia-inducible factor (HIF) under normoxic conditions, leading to HIF's degradation. Under hypoxic conditions, the activity of EGLN3 is reduced, allowing HIF to accumulate and mediate the cellular response to low oxygen, including angiogenesis, metabolism adjustment, and other survival mechanisms.

Function

EGLN3 is a prolyl hydroxylase that regulates the stability of HIF by hydroxylating it under normal oxygen levels, marking it for degradation by the proteasome. This process is crucial for the cellular adaptation to changes in oxygen availability. By controlling the levels of HIF, EGLN3 indirectly influences various physiological processes, including erythropoiesis, angiogenesis, and cellular metabolism, which are essential for the cellular response to hypoxia.

Clinical Significance

Alterations in the expression or activity of EGLN3 have been implicated in the pathogenesis of several diseases. Overexpression of EGLN3 has been observed in certain types of cancer, where it may act as a tumor suppressor by promoting apoptosis in hypoxic tumor cells. Conversely, reduced EGLN3 activity has been associated with the development of Polycythemia, a condition characterized by an increased number of red blood cells, due to the stabilization of HIF and the subsequent overproduction of erythropoietin.

Furthermore, EGLN3 has been studied for its potential role in cardiovascular diseases. Its involvement in the regulation of angiogenesis makes it a target of interest for therapeutic strategies aimed at promoting or inhibiting new blood vessel formation in conditions such as ischemic heart disease and cancer.

Genetics

The EGLN3 gene is located on chromosome 14q13.1 and consists of several exons. Variants and mutations in this gene have been studied in the context of their potential impact on the enzyme's function and the physiological processes it regulates.

Research Directions

Research on EGLN3 continues to explore its broader implications in human health and disease. Studies are investigating its role in metabolic disorders, its potential as a biomarker for hypoxia-related conditions, and its utility as a therapeutic target. The development of inhibitors or activators of EGLN3 activity holds promise for the treatment of diseases associated with dysregulated hypoxia signaling, such as certain cancers and ischemic conditions.

See Also

• Hypoxia-inducible factors
• Oxygen
• Polycythemia
• Angiogenesis

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian